Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint
Organogenesis宣布其评估ReNU安全性和有效性的3期随机对照试验达到其主要终点后,该公司股价走高
Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint
Organogenesis宣布其评估ReNU安全性和有效性的3期随机对照试验达到其主要终点后,该公司股价走高
使用浏览器的分享功能,分享给你的好友吧